RxDoctor Payments Data

Jennifer McNear, MD

Cardiovascular Disease · Augusta, GANPI 1962577239

Payments from drug & device makers

$1,259in general payments, 2019–2025

Across 72 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lexicon Pharmaceuticals, Inc.$257
  • Pfizer$205
  • Boston Scientific$137
  • E.r. Squibb & Sons, L.L.C.$131
  • Novo Nordisk$99
  • Novartis$86
  • plus $344 from 13 others

What the payments were for

  • Food & beverage$1,24599%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,259 in reported general payments places this provider in the 35th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$181,220
Medicare patients
1,631
Services billed
3,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban628$513,636
EntrestoSacubitril/Valsartan123$118,630
JardianceEmpagliflozin115$104,365
XareltoRivaroxaban62$53,993
OzempicSemaglutide13$21,412
FarxigaDapagliflozin Propanediol24$15,313
Metoprolol Succinate568$6,058
Flecainide Acetate103$4,069
Carvedilol323$2,673
Rosuvastatin Calcium136$2,056
Diltiazem 24hr Er (Cd)Diltiazem Hcl104$1,962
Atorvastatin Calcium292$1,830
Irbesartan111$1,812
Losartan Potassium191$1,544
Amlodipine Besylate243$1,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$205$513,636628 claims
NovartisEntresto$86$118,630123 claims
Boehringer IngelheimJardiance$48$104,365115 claims
Johnson & JohnsonXarelto$27$53,99362 claims
Novo NordiskOzempic$99$21,41213 claims
AstraZenecaFarxiga$29$15,31324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →